
Amy E. Juedes
Examiner (ID: 10106, Phone: (571)272-4471 , Office: P/1644 )
| Most Active Art Unit | 1644 |
| Art Unit(s) | 1644 |
| Total Applications | 1257 |
| Issued Applications | 438 |
| Pending Applications | 162 |
| Abandoned Applications | 699 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 14567401
[patent_doc_number] => 20190211307
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-07-11
[patent_title] => COMPOSITIONS AND METHODS FOR DIMINISHING AN IMMUNE RESPONSE
[patent_app_type] => utility
[patent_app_number] => 16/289095
[patent_app_country] => US
[patent_app_date] => 2019-02-28
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 21166
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -11
[patent_words_short_claim] => 30
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16289095
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/289095 | COMPOSITIONS AND METHODS FOR DIMINISHING AN IMMUNE RESPONSE | Feb 27, 2019 | Abandoned |
Array
(
[id] => 18389852
[patent_doc_number] => 20230158070
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-05-25
[patent_title] => COMBINATION COMPRISING ALLOGENEIC IMMUNE CELLS DEFICIENT FOR AN ANTIGEN PRESENT ON BOTH T-CELLS AND PATHOLOGICAL CELLS AND THERAPEUTIC ANTIBODY AGAINST SAID ANTIGEN
[patent_app_type] => utility
[patent_app_number] => 16/965834
[patent_app_country] => US
[patent_app_date] => 2019-01-30
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 46757
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -26
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16965834
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/965834 | COMBINATION COMPRISING ALLOGENEIC IMMUNE CELLS DEFICIENT FOR AN ANTIGEN PRESENT ON BOTH T-CELLS AND PATHOLOGICAL CELLS AND THERAPEUTIC ANTIBODY AGAINST SAID ANTIGEN | Jan 29, 2019 | Abandoned |
Array
(
[id] => 14309689
[patent_doc_number] => 20190144548
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-05-16
[patent_title] => Depletion of Plasmacytoid Dendritic Cells
[patent_app_type] => utility
[patent_app_number] => 16/260490
[patent_app_country] => US
[patent_app_date] => 2019-01-29
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 14228
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -14
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16260490
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/260490 | Depletion of plasmacytoid dendritic cells | Jan 28, 2019 | Issued |
Array
(
[id] => 16657699
[patent_doc_number] => 20210054335
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-02-25
[patent_title] => METHOD FOR INCREASING DENDRITIC CELL MIGRATION ABILITY, AND USE THEREOF
[patent_app_type] => utility
[patent_app_number] => 16/977320
[patent_app_country] => US
[patent_app_date] => 2019-01-28
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 7933
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -10
[patent_words_short_claim] => 21
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16977320
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/977320 | METHOD FOR INCREASING DENDRITIC CELL MIGRATION ABILITY, AND USE THEREOF | Jan 27, 2019 | Pending |
Array
(
[id] => 20185936
[patent_doc_number] => 12397036
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-08-26
[patent_title] => Peptide exchange protein
[patent_app_type] => utility
[patent_app_number] => 16/964695
[patent_app_country] => US
[patent_app_date] => 2019-01-25
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 37
[patent_figures_cnt] => 22
[patent_no_of_words] => 21026
[patent_no_of_claims] => 4
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 40
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16964695
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/964695 | Peptide exchange protein | Jan 24, 2019 | Issued |
Array
(
[id] => 16671383
[patent_doc_number] => 20210060146
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-03-04
[patent_title] => DENDRITIC CELL VACCINATION IN PARALLEL TO CHEMOTHERAPY
[patent_app_type] => utility
[patent_app_number] => 16/964863
[patent_app_country] => US
[patent_app_date] => 2019-01-25
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 12710
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -15
[patent_words_short_claim] => 26
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16964863
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/964863 | DENDRITIC CELL VACCINATION IN PARALLEL TO CHEMOTHERAPY | Jan 24, 2019 | Abandoned |
Array
(
[id] => 14467819
[patent_doc_number] => 20190185552
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-06-20
[patent_title] => Novel Use of Regulatory T Cell-Specific Surface Protein LRIG-1
[patent_app_type] => utility
[patent_app_number] => 16/233738
[patent_app_country] => US
[patent_app_date] => 2018-12-27
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 7467
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -2
[patent_words_short_claim] => 53
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16233738
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/233738 | Use of regulatory T cell-specific surface protein LRIG-1 | Dec 26, 2018 | Issued |
Array
(
[id] => 14277307
[patent_doc_number] => 20190135938
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-05-09
[patent_title] => MONOCLONAL ANTIBODIES AGAINST NKG2A
[patent_app_type] => utility
[patent_app_number] => 16/226742
[patent_app_country] => US
[patent_app_date] => 2018-12-20
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 34444
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -12
[patent_words_short_claim] => 76
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16226742
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/226742 | MONOCLONAL ANTIBODIES AGAINST NKG2A | Dec 19, 2018 | Abandoned |
Array
(
[id] => 16832149
[patent_doc_number] => 11008390
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2021-05-18
[patent_title] => Antibodies to TIGIT
[patent_app_type] => utility
[patent_app_number] => 16/228095
[patent_app_country] => US
[patent_app_date] => 2018-12-20
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 10
[patent_figures_cnt] => 12
[patent_no_of_words] => 48857
[patent_no_of_claims] => 16
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 125
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16228095
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/228095 | Antibodies to TIGIT | Dec 19, 2018 | Issued |
Array
(
[id] => 17768199
[patent_doc_number] => 11400117
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2022-08-02
[patent_title] => Compositions and methods for inhibiting T cell exhaustion
[patent_app_type] => utility
[patent_app_number] => 16/221155
[patent_app_country] => US
[patent_app_date] => 2018-12-14
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 62
[patent_figures_cnt] => 154
[patent_no_of_words] => 33370
[patent_no_of_claims] => 12
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 92
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16221155
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/221155 | Compositions and methods for inhibiting T cell exhaustion | Dec 13, 2018 | Issued |
Array
(
[id] => 16072969
[patent_doc_number] => 20200190471
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-06-18
[patent_title] => IN VITRO IMMUNE SYNAPSE SYSTEM AND METHOD OF IN VITRO EVALUATING IMMUNE RESPONSE USING THE SAME
[patent_app_type] => utility
[patent_app_number] => 16/219006
[patent_app_country] => US
[patent_app_date] => 2018-12-13
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 5870
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -10
[patent_words_short_claim] => 81
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16219006
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/219006 | IN VITRO IMMUNE SYNAPSE SYSTEM AND METHOD OF IN VITRO EVALUATING IMMUNE RESPONSE USING THE SAME | Dec 12, 2018 | Abandoned |
Array
(
[id] => 15209847
[patent_doc_number] => 20190367610
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-12-05
[patent_title] => Compositions and Methods for Regulating CAR T Cells
[patent_app_type] => utility
[patent_app_number] => 16/216460
[patent_app_country] => US
[patent_app_date] => 2018-12-11
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 17628
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -4
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16216460
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/216460 | Compositions and Methods for Regulating CAR T Cells | Dec 10, 2018 | Abandoned |
Array
(
[id] => 19651545
[patent_doc_number] => 12173316
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-12-24
[patent_title] => Compositions and methods for improving persistence of cells for adoptive transfer
[patent_app_type] => utility
[patent_app_number] => 16/769634
[patent_app_country] => US
[patent_app_date] => 2018-12-05
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 5
[patent_figures_cnt] => 9
[patent_no_of_words] => 10035
[patent_no_of_claims] => 14
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 127
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16769634
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/769634 | Compositions and methods for improving persistence of cells for adoptive transfer | Dec 4, 2018 | Issued |
Array
(
[id] => 19763348
[patent_doc_number] => 12221627
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-02-11
[patent_title] => Methods of enriching cell populations for cancer-specific T cells using in vitro stimulation of memory T cells
[patent_app_type] => utility
[patent_app_number] => 16/768930
[patent_app_country] => US
[patent_app_date] => 2018-12-03
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 32
[patent_figures_cnt] => 45
[patent_no_of_words] => 19217
[patent_no_of_claims] => 11
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 322
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16768930
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/768930 | Methods of enriching cell populations for cancer-specific T cells using in vitro stimulation of memory T cells | Dec 2, 2018 | Issued |
Array
(
[id] => 18290020
[patent_doc_number] => 11618884
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2023-04-04
[patent_title] => Regulatory T cells genetically modified for the lymphotoxin alpha gene and uses thereof
[patent_app_type] => utility
[patent_app_number] => 16/763020
[patent_app_country] => US
[patent_app_date] => 2018-11-13
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 19
[patent_figures_cnt] => 19
[patent_no_of_words] => 16995
[patent_no_of_claims] => 9
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 59
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16763020
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/763020 | Regulatory T cells genetically modified for the lymphotoxin alpha gene and uses thereof | Nov 12, 2018 | Issued |
Array
(
[id] => 16870424
[patent_doc_number] => 20210163891
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-06-03
[patent_title] => GENETICALLY ENGINEERED GAMMA DELTA T CELL
[patent_app_type] => utility
[patent_app_number] => 16/763866
[patent_app_country] => US
[patent_app_date] => 2018-11-13
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 9041
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -9
[patent_words_short_claim] => 38
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16763866
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/763866 | GENETICALLY ENGINEERED GAMMA DELTA T CELL | Nov 12, 2018 | Abandoned |
Array
(
[id] => 16913932
[patent_doc_number] => 20210187024
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-06-24
[patent_title] => NK-92 Cells to Stimulate Anti-Cancer Vaccine
[patent_app_type] => utility
[patent_app_number] => 16/760893
[patent_app_country] => US
[patent_app_date] => 2018-10-31
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 17795
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -26
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16760893
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/760893 | NK-92 Cells to Stimulate Anti-Cancer Vaccine | Oct 30, 2018 | Abandoned |
Array
(
[id] => 16629776
[patent_doc_number] => 20210048429
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-02-18
[patent_title] => PLZF+ REGULATORY CD8 T CELLS FOR CONTROL OF INFLAMMATION
[patent_app_type] => utility
[patent_app_number] => 16/758348
[patent_app_country] => US
[patent_app_date] => 2018-10-23
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 26770
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -15
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16758348
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/758348 | PLZF+ REGULATORY CD8 T CELLS FOR CONTROL OF INFLAMMATION | Oct 22, 2018 | Abandoned |
Array
(
[id] => 13904393
[patent_doc_number] => 20190041401
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-02-07
[patent_title] => Methods of Treating Subjects having Severe and/or Persistent Asthma
[patent_app_type] => utility
[patent_app_number] => 16/165402
[patent_app_country] => US
[patent_app_date] => 2018-10-19
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 25885
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -5
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16165402
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/165402 | Methods of Treating Subjects having Severe and/or Persistent Asthma | Oct 18, 2018 | Abandoned |
Array
(
[id] => 14531807
[patent_doc_number] => 20190201524
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-07-04
[patent_title] => ENHANCEMENT OF THE IMMUNE RESPONSE
[patent_app_type] => utility
[patent_app_number] => 16/165113
[patent_app_country] => US
[patent_app_date] => 2018-10-19
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 32885
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -13
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16165113
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/165113 | ENHANCEMENT OF THE IMMUNE RESPONSE | Oct 18, 2018 | Pending |